Factors affecting high-density lipoprotein cholesterol in HIV-infected patients on nevirapine-based antiretroviral therapy. 2017

C Padmapriyadarsini, and K Ramesh, and L Sekar, and Geetha Ramachandran, and Devaraj Reddy, and G Narendran, and S Sekar, and C Chandrasekar, and D Anbarasu, and Christine Wanke, and Soumya Swaminathan
Department of Clinical Research, ICMR-National Institute for Research in Tuberculosis, Chennai, India.

OBJECTIVE Cardiovascular disease (CVD) risk with low high-density lipoprotein cholesterol (HDL-C) and high triglycerides is common in the general population in India. As nevirapine (NVP)-based antiretroviral therapy (ART) tends to increase HDL-C, gene polymorphisms associated with HDL-C metabolism in HIV-infected adults on stable NVP-based ART were studied. METHODS A cross-sectional study was conducted between January 2013 and July 2014 among adults receiving NVP-based ART for 12-15 months. Blood lipids were estimated and gene polymorphisms in apolipoprotein C3 (APOC3), cholesteryl ester transfer protein (CETP) and lipoprotein lipase (LPL) genes were analyzed by real-time polymerase chain reaction. Framingham's 10-yr CVD risk score was estimated. Logistic regression was done to show factors related to low HDL-C levels. RESULTS Of the 300 patients included (mean age: 38.6±8.7 yr; mean CD4 count 449±210 cell/μl), total cholesterol (TC) >200 mg/dl was observed in 116 (39%) patients. Thirty nine per cent males and 47 per cent females had HDL-C levels below normal while 32 per cent males and 37 per cent females had TC/HDL ratio of 4.5 and 4.0, respectively. Body mass index [adjusted odds ratio (aOR)=1.70, 95% confidence interval (CI) 1.01-2.84, P=0.04] and viral load (aOR=3.39, 95% CI: 1.52-7.52, P=0.003) were negatively associated with serum HDL-C levels. The 10-yr risk score of developing CVD was 11-20 per cent in 3 per cent patients. Allelic variants of APOC3 showed a trend towards low HDL-C. CONCLUSIONS High-risk lipid profiles for atherosclerosis and cardiovascular disease were common among HIV-infected individuals, even after 12 months of NVP-based ART. Targeted interventions to address these factors should be recommended in the national ART programmes.

UI MeSH Term Description Entries
D008071 Lipoprotein Lipase An enzyme of the hydrolase class that catalyzes the reaction of triacylglycerol and water to yield diacylglycerol and a fatty acid anion. The enzyme hydrolyzes triacylglycerols in chylomicrons, very-low-density lipoproteins, low-density lipoproteins, and diacylglycerols. It occurs on capillary endothelial surfaces, especially in mammary, muscle, and adipose tissue. Genetic deficiency of the enzyme causes familial hyperlipoproteinemia Type I. (Dorland, 27th ed) EC 3.1.1.34. Heparin-Clearing Factor,Lipemia-Clearing Factor,Diacylglycerol Lipase,Diglyceride Lipase,Post-Heparin Lipase,Postheparin Lipase,Postheparin Lipoprotein Lipase,Factor, Heparin-Clearing,Factor, Lipemia-Clearing,Heparin Clearing Factor,Lipase, Diacylglycerol,Lipase, Diglyceride,Lipase, Lipoprotein,Lipase, Post-Heparin,Lipase, Postheparin,Lipase, Postheparin Lipoprotein,Lipemia Clearing Factor,Lipoprotein Lipase, Postheparin,Post Heparin Lipase
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014280 Triglycerides An ester formed from GLYCEROL and three fatty acid groups. Triacylglycerol,Triacylglycerols,Triglyceride
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D053305 Apolipoprotein C-III A 9-kDa protein component of VERY-LOW-DENSITY LIPOPROTEINS and CHYLOMICRON REMNANTS. Apo C-III, synthesized in the liver, is an inhibitor of LIPOPROTEIN LIPASE. Apo C-III modulates the binding of chylomicron remnants and VLDL to receptors (RECEPTORS, LDL) thus decreases the uptake of triglyceride-rich particles by the liver cells and subsequent degradation. The normal Apo C-III is glycosylated. There are several polymorphic forms with varying amounts of SIALIC ACID (Apo C-III-0, Apo C-III-1, and Apo C-III-2). Apo C-III,Apo C-III-2,ApoC-III,Apolipoprotein C-III-0,Apolipoprotein C-III-1,Apolipoprotein CIII,Sialyl Apo C-III,Sialyl Apolipoprotein C-III,Apo C III,Apo C III 2,Apo C-III, Sialyl,ApoC III,Apolipoprotein C III,Apolipoprotein C III 0,Apolipoprotein C III 1,Apolipoprotein C-III, Sialyl,Sialyl Apo C III,Sialyl Apolipoprotein C III

Related Publications

C Padmapriyadarsini, and K Ramesh, and L Sekar, and Geetha Ramachandran, and Devaraj Reddy, and G Narendran, and S Sekar, and C Chandrasekar, and D Anbarasu, and Christine Wanke, and Soumya Swaminathan
October 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
C Padmapriyadarsini, and K Ramesh, and L Sekar, and Geetha Ramachandran, and Devaraj Reddy, and G Narendran, and S Sekar, and C Chandrasekar, and D Anbarasu, and Christine Wanke, and Soumya Swaminathan
April 2010, HIV medicine,
C Padmapriyadarsini, and K Ramesh, and L Sekar, and Geetha Ramachandran, and Devaraj Reddy, and G Narendran, and S Sekar, and C Chandrasekar, and D Anbarasu, and Christine Wanke, and Soumya Swaminathan
July 2008, AIDS patient care and STDs,
C Padmapriyadarsini, and K Ramesh, and L Sekar, and Geetha Ramachandran, and Devaraj Reddy, and G Narendran, and S Sekar, and C Chandrasekar, and D Anbarasu, and Christine Wanke, and Soumya Swaminathan
January 2016, AIDS care,
C Padmapriyadarsini, and K Ramesh, and L Sekar, and Geetha Ramachandran, and Devaraj Reddy, and G Narendran, and S Sekar, and C Chandrasekar, and D Anbarasu, and Christine Wanke, and Soumya Swaminathan
December 2011, Antimicrobial agents and chemotherapy,
C Padmapriyadarsini, and K Ramesh, and L Sekar, and Geetha Ramachandran, and Devaraj Reddy, and G Narendran, and S Sekar, and C Chandrasekar, and D Anbarasu, and Christine Wanke, and Soumya Swaminathan
July 2001, AIDS (London, England),
C Padmapriyadarsini, and K Ramesh, and L Sekar, and Geetha Ramachandran, and Devaraj Reddy, and G Narendran, and S Sekar, and C Chandrasekar, and D Anbarasu, and Christine Wanke, and Soumya Swaminathan
March 2007, BMC infectious diseases,
C Padmapriyadarsini, and K Ramesh, and L Sekar, and Geetha Ramachandran, and Devaraj Reddy, and G Narendran, and S Sekar, and C Chandrasekar, and D Anbarasu, and Christine Wanke, and Soumya Swaminathan
July 2013, Arteriosclerosis, thrombosis, and vascular biology,
C Padmapriyadarsini, and K Ramesh, and L Sekar, and Geetha Ramachandran, and Devaraj Reddy, and G Narendran, and S Sekar, and C Chandrasekar, and D Anbarasu, and Christine Wanke, and Soumya Swaminathan
January 2004, Terapevticheskii arkhiv,
C Padmapriyadarsini, and K Ramesh, and L Sekar, and Geetha Ramachandran, and Devaraj Reddy, and G Narendran, and S Sekar, and C Chandrasekar, and D Anbarasu, and Christine Wanke, and Soumya Swaminathan
December 2012, AIDS research and human retroviruses,
Copied contents to your clipboard!